Alcoholic Cardiomyopathy
Definition
Alcoholic cardiomyopathy (ACM) is a dilated cardiomyopathy phenotype caused by long-term excessive alcohol use, characterised by dilated LV, normal or reduced LV wall thickness and mass, and HFrEF in advanced stages. It accounts for ~10% of all DCM cases in developed countries.
Key Concepts
Epidemiology
- Prevalence: 68 per 100,000 US hospitalisations; mean hospitalisation age ~56 years; higher prevalence in men. Hispanic men and women are hospitalised at younger age (~53 years). (sources/alcohol-cv-aha-2025, rating: high)
Dose and Duration
- Typical threshold: ≈7–15 standard drinks/day over 5–15 years associated with adverse systolic/diastolic ventricular function (case-control data). (sources/alcohol-cv-aha-2025, rating: high)
- As few as 4 drinks/week was associated with increased odds of diastolic dysfunction in a cross-sectional study (Daka et al.). (sources/alcohol-cv-aha-2025, rating: high)
Genetic Susceptibility — TTN Interaction
- TTN truncating variants (TTNtv) increase vulnerability to ACM: individuals with TTNtv reporting ~6 drinks/day over 5 years had significantly higher ACM risk — the strongest gene-environment interaction identified in cardiomyopathy genetics. (sources/alcohol-cv-aha-2025, rating: high)
- Alcohol functions as both an epigenetic trigger in the presence of underlying genetic variants AND a direct (non-genetic) cause of DCM. (sources/alcohol-cv-aha-2025, rating: high)
Sex Differences
- Women develop ACM at lower alcohol doses and shorter durations than men, suggesting greater alcohol-related cardiac susceptibility per unit consumed. (sources/alcohol-cv-aha-2025, rating: high)
Reversibility and Treatment
- Reduction in alcohol to <80 g/week (≈6 drinks/week) combined with guideline-concordant HF therapy improves ventricular function and prognosis. (sources/alcohol-cv-aha-2025, rating: high)
- Full cessation is the goal; even partial reduction produces measurable improvement in LVEF.
Contradictions / Open Questions
- The minimum safe threshold for alcohol in the setting of TTNtv is unknown. Given that as few as 4 drinks/week has been linked to diastolic dysfunction and TTNtv carriers are at amplified risk, no validated lower safety limit has been established for genotype-positive patients. (sources/alcohol-cv-aha-2025, rating: high)
- Alcohol-related DCM vs TTN-related DCM — classification ambiguity: When a patient with TTNtv has heavy alcohol use and DCM, attribution to alcohol vs. genetic cause is unclear. Current guidelines recognise alcohol as a "second hit" but no validated scoring tool separates these contributors clinically. (sources/alcohol-cv-aha-2025, rating: high)
- RCT evidence for alcohol reduction in ACM is limited. The evidence for recovery with alcohol reduction is predominantly observational; no RCT has prospectively tested abstinence vs. continued use in confirmed ACM with concurrent GDMT. (sources/alcohol-cv-aha-2025, rating: high)
Connections
- Related to entities/DCM — ACM is a major non-genetic DCM cause; TTNtv overlap
- Related to entities/TTN — truncating variants amplify ACM susceptibility
- Related to entities/Heart-Failure — HFrEF management applies; HF therapy + alcohol reduction improves prognosis
- Related to entities/Atrial-Fibrillation — alcohol is a causal modifiable AF trigger; abstinence reduces AF burden
- Related to concepts/Genetic-Testing-in-Cardiomyopathy — TTNtv identification changes counselling in alcohol-exposed patients
- Related to sources/alcohol-cv-aha-2025